After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ultragenyx Pharmaceutical Inc is $3.35B. A total of 0.68 million shares were traded on the day, compared to an average of 888.89K shares.
In the most recent transaction, Crombez Eric sold 520 shares of RARE for 39.24 per share on May 05 ’25. After the transaction, the EVP and Chief Medical Officer now owns 71,530 company shares. In a previous transaction on Apr 21 ’25, Crombez Eric sold 242 shares at 35.11 per share. RARE shares that EVP and Chief Medical Officer owns now total 71,680.
Among the insiders who sold shares, Horn Howard disposed of 1,785 shares on Mar 06 ’25 at a per-share price of $40.40. This resulted in the Chief Financial Officer holding 106,169 shares of RARE after the transaction. In another insider transaction, Kassberg Thomas Richard sold 6,028 shares at $42.10 per share on Mar 03 ’25. Company shares held by the CBO & EVP now total 265,238.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RARE has a high of $60.37 and a low of $29.59.
As of this writing, RARE has an earnings estimate of -$1.32 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$1.11 per share and a lower estimate of -$1.41.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $1.54, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock.
